Levetiracetam Eg Labo

Levetiracetam, the active ingredient in Levetiracetam Eg Labo, is an anticonvulsant presented as an oral formulation for oral use. It is indicated for the treatment of various seizure types in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Eg Labo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that modulates neuronal excitability and is used across several seizure disorders.

Partial seizures: reduces the frequency and severity of focal onset seizures. Generalized tonic‑clonic seizures: helps control convulsive episodes that involve the whole brain. Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: persistent tiredness or lack of energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Psychiatric changes: depression, anxiety, or suicidal thoughts. - Blood disorders: leukopenia, thrombocytopenia, or anemia. - Severe allergic reactions: anaphylaxis or angioedema. - Multi‑organ hypersensitivity: systemic inflammatory response affecting liver, kidney or lungs.

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly.

Monitor renal function: adjust dose in patients with impaired kidney function. Assess psychiatric status: watch for mood changes, depression or suicidal ideation. Avoid abrupt discontinuation: taper gradually to prevent seizure worsening. Use caution in pregnancy: limited data, weigh benefits against potential risks. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing levetiracetam levels. - Phenytoin: increases clearance, potentially decreasing efficacy. - Phenobarbital: may lower plasma concentrations of levetiracetam.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam exposure. - Oral contraceptives: possible reduction in hormonal efficacy. - Antidepressants: monitor for additive central nervous system effects. - Antipsychotics: watch for enhanced sedation. - NSAIDs: observe for increased risk of renal impairment.